Evidity Health Capital

GT Medical Technologies, Inc. is a medical device company based in Tempe, Arizona, dedicated to improving the lives of patients with brain tumors. Founded in 2017, the company has developed an innovative treatment approach through its flagship product, GammaTile, which combines a biocompatible, conformable collagen matrix with brachytherapy radiation seeds. This technology is designed to address the limitations of existing treatments for recurrent brain tumors, providing a bioresorbable solution that enhances treatment efficacy. GammaTile is protected by multiple patents and has the potential to benefit a significant patient population, with an estimated 176,000 patients diagnosed annually in the United States. To date, clinical trials at Barrow Neurological Institute have demonstrated promising outcomes, with significant clinical improvements observed in patients treated with this novel device.

Augmedics is a company that develops augmented reality-guided surgical systems aimed at enhancing the safety and outcomes of surgical procedures. Founded in 2014, the company is headquartered in Yoqneam Ilit, Israel, with an additional office located in Chicago, Illinois. Its flagship product, the xvision-spine (XVS) system, features a head-mounted display that allows surgeons to visualize the patient's anatomy through skin and tissue, significantly improving their ability to navigate during complex surgeries. The system integrates real-time positioning of surgical tools and utilizes illumination to enhance the focus area, providing critical insights and assistance to surgeons throughout the procedure. Augmedics strives to revolutionize surgical treatment by leveraging advanced technology to improve healthcare delivery.

PreludeDx develops molecular diagnostics and personalized medicine specifically for early-stage breast cancer, aiming to enhance decision-making for patients and physicians. Founded in 2009 and based in Laguna Hills, California, the company leverages technology licensed from the University of California San Francisco to create innovative tools that influence treatment options. One of its primary offerings is The DCISionRT, a test that predicts the potential benefit of radiation therapy for patients with ductal carcinoma in situ. By incorporating advancements in molecular biology, artificial intelligence, and machine learning, PreludeDx seeks to improve patient outcomes and reduce healthcare costs associated with breast cancer treatment.

Magnolia Medical Technologies, Inc. is a medical device company based in Seattle, Washington, focused on enhancing the accuracy of diagnostic blood culture tests. Established in 2011, the company has developed SteriPath, a vacuum-assisted blood collection system designed to prevent contamination of blood samples, which can lead to misdiagnosis of sepsis. This innovative system operates by actively diverting and sequestering contaminated blood, allowing for the collection of uncontaminated samples through a separate flow path. This closed vein-to-bottle collection method aims to improve diagnostic specimen quality, thereby increasing diagnostic accuracy and improving patient outcomes. Magnolia Medical Technologies holds a robust intellectual property portfolio, including over 70 issued patents and more than 50 pending applications, reflecting its commitment to advancing medical technology and addressing challenges such as antibiotic resistance. The company's products are distributed throughout the United States.

Sonde Health develops digital medicine technology that uses voice analysis to monitor and diagnose mental and physical health. The platform captures voice from mobile devices and analyzes subtle changes to measure brain, muscle, and respiratory health, enabling users to track changes over time and identify early signs of disease.

Magnolia Medical Technologies, Inc. is a medical device company based in Seattle, Washington, focused on enhancing the accuracy of diagnostic blood culture tests. Established in 2011, the company has developed SteriPath, a vacuum-assisted blood collection system designed to prevent contamination of blood samples, which can lead to misdiagnosis of sepsis. This innovative system operates by actively diverting and sequestering contaminated blood, allowing for the collection of uncontaminated samples through a separate flow path. This closed vein-to-bottle collection method aims to improve diagnostic specimen quality, thereby increasing diagnostic accuracy and improving patient outcomes. Magnolia Medical Technologies holds a robust intellectual property portfolio, including over 70 issued patents and more than 50 pending applications, reflecting its commitment to advancing medical technology and addressing challenges such as antibiotic resistance. The company's products are distributed throughout the United States.

EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company offers products such as EsophyX, which enables transoral reconstructive surgery, and the EsophyX Z device used in the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions provides SerosaFuse Fasteners, a non-resorbable polypropylene material with strength comparable to traditional sutures. Beyond its product offerings, the company supports healthcare professionals through trainer-led courses and various consultative services, including pre-authorization and medical review. Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, EndoGastric Solutions was previously known as EsophyX, Inc. before its rebranding in January 2005.

Akili Interactive Labs, Inc., established in 2011 and headquartered in Boston, Massachusetts, specializes in developing digital medicine solutions. The company's core business involves creating video game-based technology to assess and enhance cognitive abilities. Akili's broad pipeline focuses on treating cognitive deficiencies and improving symptoms associated with various medical conditions, such as ADHD, MDD, ASD, and inflammatory diseases.

Cardiva Medical, Inc. is a medical device company based in Santa Clara, California, specializing in innovative vascular access management products that facilitate the healing process following percutaneous catheterization procedures. Founded in 2002, the company develops and markets several key products, including the VASCADE VCS, an extravascular and bioabsorbable femoral access closure system that promotes rapid hemostasis while reducing complications for patients. Additionally, Cardiva offers the Cardiva CATALYST, a manual compression assistance device that enhances coagulation and provides temporary hemostasis. The company also manufactures the VASCADE MVP, designed for multi-site venous closure in electrophysiology procedures. Cardiva Medical primarily serves physicians and cardiac centers across the United States, focusing on transforming vascular closure to benefit patients and healthcare providers.

Dune Medical Devices, established in 2002, specializes in innovative tissue characterization technologies aimed at improving cancer detection and treatment. The company's flagship product, the MarginProbe™ System, utilizes a proprietary radiofrequency spectroscopy platform to provide real-time detection of cancerous tissue during surgical procedures. This system allows surgeons to assess the margins of excised tissue, addressing the critical concern of whether all cancerous cells have been removed. Clinical research has demonstrated that the use of the MarginProbe™ System significantly reduces reoperation rates for breast cancer patients, thereby enhancing the effectiveness of surgical interventions. By enabling more accurate differentiation between cancerous and healthy tissue, Dune Medical Devices aims to improve patient outcomes and streamline the cancer care experience.

Magnolia Medical Technologies, Inc. is a medical device company based in Seattle, Washington, focused on enhancing the accuracy of diagnostic blood culture tests. Established in 2011, the company has developed SteriPath, a vacuum-assisted blood collection system designed to prevent contamination of blood samples, which can lead to misdiagnosis of sepsis. This innovative system operates by actively diverting and sequestering contaminated blood, allowing for the collection of uncontaminated samples through a separate flow path. This closed vein-to-bottle collection method aims to improve diagnostic specimen quality, thereby increasing diagnostic accuracy and improving patient outcomes. Magnolia Medical Technologies holds a robust intellectual property portfolio, including over 70 issued patents and more than 50 pending applications, reflecting its commitment to advancing medical technology and addressing challenges such as antibiotic resistance. The company's products are distributed throughout the United States.

Cardiva Medical, Inc. is a medical device company based in Santa Clara, California, specializing in innovative vascular access management products that facilitate the healing process following percutaneous catheterization procedures. Founded in 2002, the company develops and markets several key products, including the VASCADE VCS, an extravascular and bioabsorbable femoral access closure system that promotes rapid hemostasis while reducing complications for patients. Additionally, Cardiva offers the Cardiva CATALYST, a manual compression assistance device that enhances coagulation and provides temporary hemostasis. The company also manufactures the VASCADE MVP, designed for multi-site venous closure in electrophysiology procedures. Cardiva Medical primarily serves physicians and cardiac centers across the United States, focusing on transforming vascular closure to benefit patients and healthcare providers.

Akili Interactive Labs, Inc., established in 2011 and headquartered in Boston, Massachusetts, specializes in developing digital medicine solutions. The company's core business involves creating video game-based technology to assess and enhance cognitive abilities. Akili's broad pipeline focuses on treating cognitive deficiencies and improving symptoms associated with various medical conditions, such as ADHD, MDD, ASD, and inflammatory diseases.

Biotheranostics, Inc. is a commercial-stage molecular diagnostics company based in San Diego, California, specializing in the discovery, development, and commercialization of proprietary diagnostic, prognostic, and predictive tests aimed at enhancing cancer treatment. The company offers a range of innovative tests, including the Breast Cancer Index, which assists oncologists in making informed decisions regarding extended endocrine therapy for estrogen receptor-positive breast cancer patients. Additionally, CancerTYPE ID provides critical genomic information for the diagnosis and treatment of metastatic cancer, while the bioT3 metastatic cancer solution integrates precise molecular diagnosis with comprehensive biomarker data to improve treatment options for metastatic cancer patients. With a CLIA-certified and CAP-accredited laboratory, Biotheranostics is licensed to perform testing across all 50 states, positioning itself as a leader in addressing unmet medical needs in oncology.

Tryton Medical, Inc. is a medical device company based in Durham, North Carolina, specializing in the development and manufacture of side branch stent systems designed for the treatment of coronary bifurcation lesions. Established in 2003, the company focuses on addressing cardiovascular diseases by providing innovative solutions, particularly through its flagship product, the Tryton Side Branch Stent System. This system offers a targeted approach to treating atherosclerotic lesions located in the side branches at bifurcation sites. Tryton Medical distributes its products internationally and also caters to investigational needs within the United States, demonstrating its commitment to advancing cardiovascular care in various markets, including Europe and beyond.

Cardiva Medical, Inc. is a medical device company based in Santa Clara, California, specializing in innovative vascular access management products that facilitate the healing process following percutaneous catheterization procedures. Founded in 2002, the company develops and markets several key products, including the VASCADE VCS, an extravascular and bioabsorbable femoral access closure system that promotes rapid hemostasis while reducing complications for patients. Additionally, Cardiva offers the Cardiva CATALYST, a manual compression assistance device that enhances coagulation and provides temporary hemostasis. The company also manufactures the VASCADE MVP, designed for multi-site venous closure in electrophysiology procedures. Cardiva Medical primarily serves physicians and cardiac centers across the United States, focusing on transforming vascular closure to benefit patients and healthcare providers.

Dune Medical Devices, established in 2002, specializes in innovative tissue characterization technologies aimed at improving cancer detection and treatment. The company's flagship product, the MarginProbe™ System, utilizes a proprietary radiofrequency spectroscopy platform to provide real-time detection of cancerous tissue during surgical procedures. This system allows surgeons to assess the margins of excised tissue, addressing the critical concern of whether all cancerous cells have been removed. Clinical research has demonstrated that the use of the MarginProbe™ System significantly reduces reoperation rates for breast cancer patients, thereby enhancing the effectiveness of surgical interventions. By enabling more accurate differentiation between cancerous and healthy tissue, Dune Medical Devices aims to improve patient outcomes and streamline the cancer care experience.